Abstract
Early phase clinical trials provide an initial evaluation of therapies’ risks and benefits to patients, including safety and tolerability, which typically relies on reporting outcomes by investigator and laboratory assessments. Use of patient-reported outcomes (PROs) to inform risks (tolerability) and benefits (improvement in disease symptoms) is more common in later than early phase trials. We convened a two-day expert roundtable covering: (1) the necessity and feasibility of a universal PRO core conceptual model for early phase trials; (2) the practical integration of PROs in early phase trials to inform tolerability assessment, guide dose decisions, or as real-time safety alerts to enhance investigator-reported adverse events. Participants (n = 22) included: patient advocates, regulators, clinicians, statisticians, pharmaceutical representatives, and PRO methodologists working across diverse clinical areas. In this manuscript, we report major recommendations resulting from the roundtable discussions corresponding to each theme. Additionally, we highlight priority areas necessitating further investigation.
Original language | English |
---|---|
Article number | 102838 |
Number of pages | 13 |
Journal | EClinicalMedicine |
Volume | 76 |
Early online date | 24 Sept 2024 |
DOIs | |
Publication status | Published - Oct 2024 |
Keywords
- Patient-reported outcomes
- Dose-finding
- Phase I
- Phase II
- Early phase trials
- Tolerability
- Patient-centred clinical development
- Quality of life
- Trial designs